:format(webp)/cdn.mskdoctors.com/storage/2026/8/bwZtSBcMngYTVd0Ea9Zvwh22yrzaDzib.jpg)
ACI versus MACI for knee cartilage repairCartilage defect size on MRI drives the choice between single-stage repair (AMIC, OATS) and two-stage cell therapy (MACI): below 2–4 cm², simpler alternatives often provide comparable results; at 3 cm² or larger, MACI demonstrates superiority.Cartilage defect size on MRI drives the choice between single-stage repair (AMIC, OATS) and two-stage cell therapy (MACI): below 2–4 cm², simpler alternatives often provide comparable results; at 3 cm² or larger, MACI demonstrates superiority.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/WyTUgPyuRTUUHCpsWkxQLHIH1zV03yj2.jpg)
Can ChondroFiller delay joint replacement?An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/2of3MbpwJvcJrDYn03x9VVz3ZGqDUeFf.jpg)
ChondroFiller vs hyaluronic acid for cartilage repairChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/766rT75vrzgAcHwc9vxAXYr5JrU3PaGe.jpg)
ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/9Hqd2xvHBuvx5OPeQiMHYCExN1B2atBZ.jpg)
ChondroFiller injection for ankle cartilage defectsChondroFiller is an acellular collagen scaffold that fills talar cartilage defects without tissue harvest or surgery: it gels within the lesion and recruits the patient's own progenitor cells to drive repair. Delivered under ultrasound guidance as an outpatient procedure, it requires no general anaesthetic or theatre admission.ChondroFiller is an acellular collagen scaffold that fills talar cartilage defects without tissue harvest or surgery: it gels within the lesion and recruits the patient's own progenitor cells to drive repair. Delivered under ultrasound guidance as an outpatient procedure, it requires no general anaesthetic or theatre admission.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/8Ybarca5EyikHWwPNDgHdzL8O444HHna.jpg)
AMIC vs MACI for knee cartilage repairStandalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².Standalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².
:format(webp)/cdn.mskdoctors.com/storage/2026/7/8ilKw2XCH5pB5TWOt6kewJNVnwz4zE0V.jpg)
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/ETKg1ueF5BBKIau7DxGIoPsVzI5r2krh.jpg)
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/YjVRrObruXhFRSj4s2XzPrviUN6lGG71.jpg)
Cartilage Specialist or General Orthopaedic SurgeonFocal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.Focal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/jsvrgfCOH4IBtCsmXXnshr2LWJGubdnf.jpg)
MACI versus microfracture for knee cartilage repairMACI outperforms microfracture for knee cartilage defects of 3 cm² or larger, according to the SUMMIT randomised trial, which found significantly greater improvements in pain and function at two years that persisted through five years.MACI outperforms microfracture for knee cartilage defects of 3 cm² or larger, according to the SUMMIT randomised trial, which found significantly greater improvements in pain and function at two years that persisted through five years.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/kdJLYT4OrqCVc66Qt59MAYpEnxqzgZZ2.jpg)
AMIC vs microfracture for knee cartilage repairBoth AMIC and microfracture improve pain and function in the first two years; beyond that point, microfracture outcomes progressively deteriorate whilst AMIC maintains stable gains through a decade of follow-up.Both AMIC and microfracture improve pain and function in the first two years; beyond that point, microfracture outcomes progressively deteriorate whilst AMIC maintains stable gains through a decade of follow-up.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/UY0InSBaoOinSJHR9T3qmZrV7DMIQOXA.jpg)
ChondroFiller vs PRP for focal cartilage defectsFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying…Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
